News items related to: News
-
What community activism can achieve – ITPC’s 2017 Annual Review
ITPC is proud to share its 2017 Annual Review, titled What Community Activism Can Achieve. The report highlights our successes, challenges, and...
-
When will ViiV, Clinton Health and partners officially repair the mistake on missing out 39 countries from the DTG pricing agreement?
It has been six months since we alerted the Clinton Health Access Initiative (CHAI) to a glaring omission in the...
-
MMA position on DTG after trials identify potential safety concerns for use at the time of conception
Doultegravir (DTG) is a highly effective, tolerable antiretroviral medicine with a high barrier to resistance; in 2015, WHO recommended it...
-
Five years after the Indian Supreme Court’s Novartis verdict
Five years after this landmark decision, the impact is being felt around the world. India’s decision is frequently held up...
-
Patent backlogs fuel efforts to extend pharma patent terms in Thailand and Brazil, AIDS activists say
Excessive patenting in the multinational pharmaceutical sector, along with a huge backlog, works in Big Pharma’s favour. Civil society is...
-
Groups target EU-Mercosur FTA to advance access to health in trade deals
AIDS activists, health activists and civil society organizations in Brazil and Argentina are pushing back against the negative effects of...
-
Collective efforts by civil society groups bar the way to Hepatitis C patents
Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position...
-
Truvada case shows civil society’s success with pre-grant opposition
The example of Gilead antiretroviral Truvada in Argentina and Brazil shows how civil society efforts to use patent opposition to...
-
Thailand: Evergreened patents cause unwarranted high drug prices
Transnational drug manufacturers’ tactics of obtaining unmerited patent applications have unnecessarily raised healthcare costs and impeded the growth of domestic...
-
Civil society key in TRIPS flexibility implementation
Civil society plays an instrumental role in actively defending access to affordable to medicines, making use of TRIPS flexibilities, and...
-
Launched: I-MAK’s Special Edition Roadmap on Tenofovir Alafenamide Fumarate (TAF)
A critical analysis of TAF, as part of a Roadmap series, aims to help the international community assess the best...
-
Gilead’s patent application on sofosbuvir rejected in Brazil
Rejected! That was the decision issued by Brazil’s National Institute of Industrial Property (INPI) over one of Gilead’s patent applications...